Sandra Julia Rosenbaum-Krumme

Learn More
The aim of this study was to compare integrated PET/CT and PET/MRI for their usefulness in detecting and categorizing cervical iodine-positive lesions in patients with differentiated thyroid cancer using 124I as tracer. The study group comprised 65 patients at high risk of iodine-positive metastasis who underwent PET/CT (low-dose CT scan, PET acquisition(More)
AIM A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. PATIENTS, METHODS The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy(More)
PURPOSE Morphologic imaging after radiofrequency ablation (RFA) of liver metastases is hampered by rim-like enhancement in the ablation margin, making the identification of local tumor progression (LTP) difficult. Follow-up with PET/CT is compared to follow-up with PET alone and MRI after RFA. METHODS AND MATERIALS Sixteen patients showed 25 FDG-positive(More)
PURPOSE This study compares intrinsically coregistered 124I positron emission tomography (PET) and CT (PET/CT) and software coregistered 124I PET and MRI (PET/MRI) images for the diagnosis and dosimetry of thyroid remnant tissues and lymph node metastases in patients with differentiated thyroid carcinoma (DTC). METHODS After thyroidectomy, 33 high-risk(More)
UNLABELLED (124)I PET/CT images from differentiated thyroid cancer patients were retrospectively analyzed to assess the relationship between absorbed radiation dose (AD) to lesions and their response after radioiodine therapy. METHODS Patients received serial (124)I PET/CT scans before and after their first radioiodine treatment. The pretherapy PET data(More)
OBJECTIVES To compare [(18)F]FDG PET/MRI with PET/CT for the assessment of bone lesions in oncologic patients. METHODS This prospective study included 67 patients with solid tumours scheduled for PET/CT with [(18)F]FDG who also underwent a whole-body PET/MRI scan. The datasets (PET/CT, PET/MRI) were rated by two readers regarding lesion conspicuity(More)
(124)I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination (124)I-PET and CT allows foci of highly specific (124)I uptake to be localized with a low radiation dose, which is specifically important(More)
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art(More)
PURPOSE Advanced tumour stage and initial metastases are associated with reduced general and tumour-free survival in patients with differentiated thyroid carcinoma. Optimal initial therapy is mandatory for a positive patient outcome, but can only be performed if all non-iodine-avid tumour lesions are known before planning treatment. We analysed the benefit(More)
UNLABELLED Serum thyroglobulin (Tg) is a reliable tumour marker in follow-up of patients with differentiated thyroid carcinoma (DTC). A positive correlation between Tg level and tumour mass was recently observed, but no attempts were made to derive a numerical relation. The aim of this study was to derive a numerical relationship between serum Tg level and(More)